# A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Source: https://onco.cc/trials/nct06015048/  
OnCo record `nct06015048` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pyrotinib and Trastuzumab rezetecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT06015048 by Jiangsu HengRui Medicine Co., Ltd., with 364 participants planned, started 2023-08-11 and due to reach its primary completion in 2026-11. Interventions recorded: SHR-A1811 combined with Pyrotinib. and SHR-A1811 combined with other antitumor therapies.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06015048
- Phase: 1/2
- Setting: A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Efficacy of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 364

## Sources

- ClinicalTrials.gov NCT06015048: https://clinicaltrials.gov/study/NCT06015048

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pyrotinib](https://onco.cc/drugs/pyrotinib/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06015048.json